
X
Pfizer petitions FDA to clamp down on biosimilar ‘scare tactics’
https://pharmaphorum.com/news/pfizer-petitions-fda-to-clamp-down-on-biosimilar-scare-tactics/
Lupin’s biosimilar is under review in EU
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
Mylan takes aim at Allergan’s off-patent blockbuster